Aquestive Therapeutics 公布 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究积极结果

美股速递08-10

Aquestive Therapeutics 近日公布了其明星产品 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究的积极顶线结果。这一成果标志着该候选药物在过敏性反应紧急治疗领域迈出了关键一步。研究数据表明，在模拟真实使用场景的人因工程测试中，受试者能够正确、迅速地完成给药操作；同时，药代动力学分析显示，药物吸收迅速，血药浓度达峰时间理想，展现出良好的生物利用度。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1148477646?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-10 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148477646","market":"us","top_or_hot":-1,"title":"Aquestive Therapeutics 公布 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究积极结果","media":"美股速递","content":"<p>Aquestive Therapeutics 近日公布了其明星产品 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究的积极顶线结果。这一成果标志着该候选药物在过敏性反应紧急治疗领域迈出了关键一步。研究数据表明，在模拟真实使用场景的人因工程测试中，受试者能够正确、迅速地完成给药操作；同时，药代动力学分析显示，药物吸收迅速，血药浓度达峰时间理想，展现出良好的生物利用度。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aquestive Therapeutics 公布 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAquestive Therapeutics 公布 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-10 19:06 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aquestive Therapeutics 近日公布了其明星产品 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究的积极顶线结果。这一成果标志着该候选药物在过敏性反应紧急治疗领域迈出了关键一步。研究数据表明，在模拟真实使用场景的人因工程测试中，受试者能够正确、迅速地完成给药操作；同时，药代动力学分析显示，药物吸收迅速，血药浓度达峰时间理想，展现出良好的生物利用度。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1148477646","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148477646","pubTimestamp":1786359965,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Aquestive Therapeutics 近日公布了其明星产品 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究的积极顶线结果。这一成果标志着该候选药物在过敏性反应紧急治疗领域迈出了关键一步。研究数据表明，在模拟真实使用场景的人因工程测试中，受试者能够正确、迅速地完成给药操作；同时，药代动力学分析显示，药物吸收迅速，血药浓度达峰时间理想，展现出良好的生物利用度。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","AQST":"Aquestive Therapeutics Inc."},"translate_title":"Aquestive Therapeutics Announces Anaphylm ™ Positive results of human engineering and pharmacokinetic studies of (dibutyl epinephrine) sublingual membrane","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AQST":1},"content_text":"Aquestive Therapeutics 近日公布了其明星产品 Anaphylm™（二丁基肾上腺素）舌下膜剂的人因工程与药代动力学研究的积极顶线结果。这一成果标志着该候选药物在过敏性反应紧急治疗领域迈出了关键一步。研究数据表明，在模拟真实使用场景的人因工程测试中，受试者能够正确、迅速地完成给药操作；同时，药代动力学分析显示，药物吸收迅速，血药浓度达峰时间理想，展现出良好的生物利用度。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148477646","isCrawlerRequest":true}